| Dr Lauren Leigh Knight, MD | |
|
1600 Wallace Blvd, Amarillo, TX 79106-1799 | |
| (806) 212-2129 | |
| (806) 212-2246 |
| Full Name | Dr Lauren Leigh Knight |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 7 Years |
| Location | 1600 Wallace Blvd, Amarillo, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407353931 | NPI | - | NPPES |
| 416832003 | Medicaid | TX | |
| 1Q8749 | Other | TX | MEDICARE PTAN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist St Anthony's Hospital | Amarillo, TX | Hospital |
| Memorial Hospital | Dumas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bsa Physicians Group Inc | 3971748146 | 90 |
| Moore County Hospital District | 1254226269 | 33 |
News Archive
Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.
A nationwide survey of the religious beliefs and practices of American physicians has found that the least religious of all medical specialties is psychiatry.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
"Last week a global health event took place in Dar Es Salaam, Tanzania, to foster greater political will and explore ways to accelerate results, innovation, sustainability, and equity in the field of immunization," Baroness Hollins, emeritus professor of psychiatry of disability at St George's University of London, writes in the BMJ Group Blog about the GAVI Partners Forum.
› Verified 3 days ago
| Entity Name | Moore County Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700991700 PECOS PAC ID: 1254226269 Enrollment ID: O20040430000610 |
News Archive
Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.
A nationwide survey of the religious beliefs and practices of American physicians has found that the least religious of all medical specialties is psychiatry.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
"Last week a global health event took place in Dar Es Salaam, Tanzania, to foster greater political will and explore ways to accelerate results, innovation, sustainability, and equity in the field of immunization," Baroness Hollins, emeritus professor of psychiatry of disability at St George's University of London, writes in the BMJ Group Blog about the GAVI Partners Forum.
› Verified 3 days ago
| Entity Name | Southwest Medical Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831299122 PECOS PAC ID: 6204882947 Enrollment ID: O20050325000524 |
News Archive
Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.
A nationwide survey of the religious beliefs and practices of American physicians has found that the least religious of all medical specialties is psychiatry.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
"Last week a global health event took place in Dar Es Salaam, Tanzania, to foster greater political will and explore ways to accelerate results, innovation, sustainability, and equity in the field of immunization," Baroness Hollins, emeritus professor of psychiatry of disability at St George's University of London, writes in the BMJ Group Blog about the GAVI Partners Forum.
› Verified 3 days ago
| Entity Name | Quantum Emergency Physicians Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215010079 PECOS PAC ID: 1153414503 Enrollment ID: O20070830000804 |
News Archive
Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.
A nationwide survey of the religious beliefs and practices of American physicians has found that the least religious of all medical specialties is psychiatry.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
"Last week a global health event took place in Dar Es Salaam, Tanzania, to foster greater political will and explore ways to accelerate results, innovation, sustainability, and equity in the field of immunization," Baroness Hollins, emeritus professor of psychiatry of disability at St George's University of London, writes in the BMJ Group Blog about the GAVI Partners Forum.
› Verified 3 days ago
| Entity Name | Bsa Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457696916 PECOS PAC ID: 3971748146 Enrollment ID: O20130319000147 |
News Archive
Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.
A nationwide survey of the religious beliefs and practices of American physicians has found that the least religious of all medical specialties is psychiatry.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
"Last week a global health event took place in Dar Es Salaam, Tanzania, to foster greater political will and explore ways to accelerate results, innovation, sustainability, and equity in the field of immunization," Baroness Hollins, emeritus professor of psychiatry of disability at St George's University of London, writes in the BMJ Group Blog about the GAVI Partners Forum.
› Verified 3 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.
A nationwide survey of the religious beliefs and practices of American physicians has found that the least religious of all medical specialties is psychiatry.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
"Last week a global health event took place in Dar Es Salaam, Tanzania, to foster greater political will and explore ways to accelerate results, innovation, sustainability, and equity in the field of immunization," Baroness Hollins, emeritus professor of psychiatry of disability at St George's University of London, writes in the BMJ Group Blog about the GAVI Partners Forum.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lauren Leigh Knight, MD Po Box 840026, Dallas, TX 75284-0026 Ph: (806) 212-5079 | Dr Lauren Leigh Knight, MD 1600 Wallace Blvd, Amarillo, TX 79106-1799 Ph: (806) 212-2129 |
News Archive
Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.
A nationwide survey of the religious beliefs and practices of American physicians has found that the least religious of all medical specialties is psychiatry.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
"Last week a global health event took place in Dar Es Salaam, Tanzania, to foster greater political will and explore ways to accelerate results, innovation, sustainability, and equity in the field of immunization," Baroness Hollins, emeritus professor of psychiatry of disability at St George's University of London, writes in the BMJ Group Blog about the GAVI Partners Forum.
› Verified 3 days ago
Ali Abdulsattar Hussein, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 6700 W 9th Ave, Amarillo, TX 79106 Phone: 806-358-0200 Fax: 806-356-5590 | |
Lowell Gay Rollins Iii, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1600 Wallace Blvd, Amarillo, TX 79106 Phone: 806-212-2129 Fax: 806-212-2246 | |
Laura Gomez, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1400 S Coulter St, Amarillo, TX 79106 Phone: 806-414-9559 | |
Todd Bell, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1400 S Coulter, Amarillo, TX 79106 Phone: 806-354-5660 Fax: 806-354-5717 | |
Bennet Graham, FNP-C Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1400 S Coulter St, Amarillo, TX 79106 Phone: 806-414-9558 Fax: 806-354-5561 | |
Dr. Chaminda Fernando, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1301 S Coulter St, Suite 405, Amarillo, TX 79106 Phone: 806-358-9111 Fax: 806-358-3728 | |
Omar Bazzaz, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 1501 S Coulter St, Amarillo, TX 79106 Phone: 806-354-1000 |